Browsing Wolfson Institute of Preventive Medicine by Author "MacCallum, P"
Now showing items 1-15 of 15
-
Automated measurement of coagulation and fibrinolytic activation markers: Outcomes in coronavirus disease 2019 (COVID-19) patients
Gardiner, C; Mackie, IJ; MacCallum, P; Platton, S (2022) -
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Young, AM; Marshall, A; Thirlwall, J; Chapman, O; Lokare, A; Hill, C; Hale, D; Dunn, JA; Lyman, GH; Hutchinson, C (2018-07-10)Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was to assess if ... -
Direct oral anti-coagulants for prevention of stroke and systemic embolism in non-valvular atrial fibrillation - Barts Health experience across two sites
Kalkur, P; Kreze, O; Chauhan, N; Lim, S; Antoniou, S; MacCallum, P; Bowles, L (2015-04) -
Effect of argatroban on laboratory measurement of fibrinogen activity in ex vivo samples - Potential for errors in clinical decision-making
Platton, S; Hill, C; Lester, W; Yartey, N; MacCallum, P (2023) -
Effects of rivaroxaban on routine coagulation screening tests using commonly used reagents
Platton, S; Bowles, L; MacCallum, P (2017-11) -
Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials.
Barco, S; Virdone, S; Götschi, A; Ageno, W; Arcelus, JI; Bingisser, R; Colucci, G; Cools, F; Duerschmied, D; Gibbs, H (2023-08-18)BACKGROUND: Antithrombotic treatment may improve the disease course in non-critically ill, symptomatic COVID-19 outpatients. METHODS: We performed an individual patient-level analysis of the OVID and ETHIC randomized ... -
Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination
Platton, S; Bartlett, A; MacCallum, P; Makris, M; McDonald, V; Singh, D; Scully, M; Pavord, S (2021-08) -
The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE.
Goto, S; Turpie, AGG; Farjat, AE; Weitz, JI; Haas, S; Ageno, W; Goldhaber, SZ; Angchaisuksiri, P; Kayani, G; MacCallum, P (2021-07)INTRODUCTION: Clinical characteristics and outcomes of venous thromboembolism (VTE) patients with concomitant anemia are unclear. This study compares baseline characteristics, treatment patterns, and 24-month outcomes in ... -
Influence of Body Mass Index on Clinical Outcomes in Venous Thromboembolism: Insights from GARFIELD-VTE.
Weitz, JI; Farjat, AE; Ageno, W; Turpie, AG; Haas, S; Goto, S; Goldhaber, SZ; Angchaisuksiri, P; Gibbs, H; MacCallum, P (2021-09-06)BACKGROUND: There is limited information on the influence of body mass index (BMI) on clinical outcomes in patients with venous thromboembolism (VTE). OBJECTIVES: Investigate the influence of BMI on baseline characteristics, ... -
Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE
Cohen, O; Ageno, W; Farjat, AE; Turpie, AGG; Weitz, JI; Haas, S; Goto, S; Goldhaber, SZ; Angchaisuksiri, P; Gibbs, H (2022) -
On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease.
Haas, S; Farjat, AE; Pieper, K; Ageno, W; Angchaisuksiri, P; Bounameaux, H; Goldhaber, SZ; Goto, S; Mantovani, L; Prandoni, P (2022-10)Background Direct oral anticoagulants (DOACs) provide a safe, effective alternative to vitamin K antagonists (VKAs) for venous thromboembolism (VTE) treatment, as shown via intention-to-treat comparative effectiveness ... -
Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE.
Jerjes-Sánchez, C; Rodriguez, D; Farjat, AE; Kayani, G; MacCallum, P; Lopes, RD; Turpie, AGG; Weitz, JI; Haas, S; Ageno, W (2021-01)Introduction The risk of venous thromboembolism (VTE) increases during pregnancy and the puerperium such that VTE is a leading cause of maternal mortality. Methods We describe the clinical characteristics, diagnostic ... -
Renal transplant and hemostasis: early postoperative changes in recipients and donors.
Kohli, R; Platton, S; Forbes, S; Thuraisingham, R; Tan, J; Green, L; MacCallum, P (2023-05)BACKGROUND: The benefit of administering pharmacologic thromboprophylaxis following renal transplantation remains uncertain. OBJECTIVES: To compare hemostatic parameters before and after renal transplant surgery in both ... -
A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study)
Green, L; Tan, J; Morris, JK; Alikhan, R; Curry, N; Everington, T; Maclean, R; Saja, K; Stanworth, S; Tait, C (2018-03-23) -
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial
Cools, F; Virdone, S; Sawhney, J; Lopes, RD; Jacobson, B; Arcelus, JI; Hobbs, FDR; Gibbs, H; Himmelreich, JCL; MacCallum, P (2022)